An observational study in Multiple Sclerosis Relapse, Surgery and Anesthesia, sponsored by University of Athens. Recruiting at 2 sites in Greece. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-01-23.
Sponsored by University of Athens · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Multiple Sclerosis with a site in Greece — 6 open to participants now, 17 under way, 8 of them phase 3. Multiple Sclerosis · Greece.
Among the 69 studies in Multiple Sclerosis with a site in Greece, this one is the 6th largest by planned enrollment of the 14 observational ones that give a count, is one of 5 that started in 2019, is one of 14 observational ones, reaches primary completion later than 9 of the 16 other live ones, and was the 43rd registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →6 of the 69 studies in Multiple Sclerosis with a site in Greece are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Greece, United States, Argentina and 33 more countries
Ages 18–65
University of Patras · Sites in Greece
Ages 18+
Novartis Pharmaceuticals · Sites in Greece, United States, Argentina and 16 more countries
Ages 40–70
Novartis Pharmaceuticals · Sites in Greece
Ages 18–55
The Foundation for Orthopaedics and Regenerative Medicine · Sites in Greece, United States
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 38 · Phase 4 2
First in 2006; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 751 across the 55 interventional studies, 255 across the 14 observational. Of the 52 that completed or were terminated, 33 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 69 have an industry lead sponsor. The 10 most frequent:
University of Athens is the lead sponsor of 139 studies on the registry; 19 are open to participants now.
University of Athens has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Multiple Sclerosis with a site in Greece that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
Add it to your calendar (.ics) → With an account.
Among the 69 studies in Multiple Sclerosis with a site in Greece, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to record any relapses during one year postoperatively in patients and parturients diagnosed with MS who received general or regional anesthesia
patients or parturients with MS who received general or regional anesthesia for surgery or labor analgesia
Inclusion Criteria: diagnosed MS -
Exclusion Criteria: refuse to participate
-
Procedure: surgery and anesthesia
Procedure: surgery and anesthesia
patients with MS who received general or regional anesthesia for a surgery or labor
MS relapses
number of relapses
Time frame: one year postoperatively
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2019 (actual). Primary completion is estimated for Dec 2027, 96 months after the start.
Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 96 months is above that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.